Form 4: Teladoc Health Executive Kelly Bliss Reports Stock Transactions
SEC Form 4 Filing
Kelly Bliss, President, U.S. Group Health at Teladoc Health, reported the acquisition and disposal of Teladoc Health common stock and derivative securities.
Summary
- On February 28, 2025, Kelly Bliss, President, U.S. Group Health at Teladoc Health, exercised restricted stock units and performance stock units, converting them into common stock.
- Specifically, 1,404 restricted stock units from a 2022 grant, 3,488 restricted stock units from a 2023 grant, and 1,189 performance stock units from a 2024 grant were converted.
- On March 3, 2025, 2,904 shares were sold at a price of $9.684 to cover tax obligations related to the vesting of these units.
- Additionally, on March 1, 2025, Bliss was granted 109,832 restricted stock units, vesting over time.
Sentiment
Score: 5
Explanation: This is a neutral document detailing stock transactions. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Comparison to Industry Standards
- Executive compensation packages, including stock options and restricted stock units, are standard practice in publicly traded companies like Teladoc Health to incentivize performance and align executive interests with shareholder value.
- The vesting schedules and terms of these equity grants are generally comparable to those offered by other companies in the healthcare technology sector, such as Amwell or Accolade.
- Sales of shares to cover tax obligations upon vesting are also a common occurrence among executives receiving equity compensation.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the sale of shares to cover tax obligations, but the overall impact is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 03/01/2022 | Reporting person was granted 16,844 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 03/03/2023 | Reporting person was granted 41,853 restricted stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 03/01/2024 | Reporting person earned 14,263 performance stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 02/28/2025 | Restricted stock units and performance stock units converted to shares of TDOC common stock. |
| 03/01/2025 | 109,832 restricted stock units were granted, vesting over time. |
| 03/03/2025 | 2,904 shares sold to cover tax obligations at $9.684 per share. |
| 03/04/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.